HOERSHOLM, Denmark and SAN DIEGO, California, September 16 /PRNewswire/ --
- Denmark-Based Santaris Pharma A/S Appoints Leading RNA Industry Expert Art Levin Ph.D. as President of US Operations and Chief Development Officer
- Utilizing its Proprietary RNA Chemistry - Locked Nucleic Acid (LNA) -and Drug Discovery Engine, the US Subsidiary Aims to Foster Relationships With New Partners, Increase Visibility With Capital Markets and Attract Leading Scientists
- Santaris Pharma A/S is First Company to Advance a microRNA-Targeted Drug into Human Clinical Trials; SPC3649 Targets miR-122 for the Treatment of Hepatitis C
- Recently Announced Strategic Alliance With Shire Demonstrates LNA is Rapidly Becoming the Chemistry-of-Choice and Adds to the Growing List of mRNA and microRNA Drug Discovery and Development Partnerships That Include Wyeth, GlaxoSmithKline and Enzon for a Range of Diseases
Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced it has established operations in the United States. Internally and through its partners, the Company has a robust drug development pipeline including programs to treat metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders.
Increasing interest, new collaborations and breakthrough advancements utilizing the Company's proprietary RNA-based Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine led Santaris Pharma A/S, headquartered in Denmark, to establish US-based operations in San Diego, California.
To spearhead the US expansion, Santaris Pharma A/S has appointed leading
RNA industry expert Arthur A. Levin, PhD, as President of its US operations.
In addition, Dr. Levin will hold global responsibility as Vice President and
Chief Development Officer
|SOURCE Santaris Pharma A/S|
Copyright©2009 PR Newswire.
All rights reserved